Rekombinanter IL13 (Lebrikizumab Biosimilar) Antikörper
Research Grade
Reaktivität: Human
ELISA
Wirt: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target
- IL13 (Lebrikizumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
- Wirt
-
Mammalian Cells
- Expressionssystem
- Mammalian cells
- Klonalität
- Monoklonal
- Applikation
- ELISA
- Verwendungszweck
- Lebrikizumab Biosimilar - Anti-IL13 mAb
- Produktmerkmale
- Antibody Type: IgG4-kappa
- Aufreinigung
- Recombinant antibody expressed in mammalien cells and purified.
- Güteklasse
- Research Grade
- Isotyp
- IgG4 kappa
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- PBS pH 7.5
- Lagerung
- -80 °C
- Informationen zur Lagerung
- store at -80°C
-
- Target
- IL13 (Lebrikizumab Biosimilar)
- Substanzklasse
- Biosimilar
- Hintergrund
-
MILR1444A,PRO301444
Lebrikizumab is a humanized monoclonal antibody targeting IL13, it is an experimental immunosuppressive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. - CAS-Nummer
- 953400-68-5
-
Sie sind hier:
